Tarlatamab plus anti-PD-L1 as first-line maintenance for ES-SCLC demonstrates promising results.
0/5 보강
APA
Lawrence L (2026). Tarlatamab plus anti-PD-L1 as first-line maintenance for ES-SCLC demonstrates promising results.. Cancer, 132(1), e70179. https://doi.org/10.1002/cncr.70179
MLA
Lawrence L. "Tarlatamab plus anti-PD-L1 as first-line maintenance for ES-SCLC demonstrates promising results.." Cancer, vol. 132, no. 1, 2026, pp. e70179.
PMID
41482887 ↗
같은 제1저자의 인용 많은 논문 (5)
- FDA approves perioperative pembrolizumab plus enfortumab vedotin for cisplatin-ineligible MIBC.
- Adding pembrolizumab to a platinum doublet may be a new option for advanced penile cancer.
- Two new options for NPM1-mutated relapsed, refractory acute myeloid leukemia: Researchers are looking into whether revumenib or ziftomenib can be combined with first-line standard-of-care treatment options.
- Joint guideline update recommendations for postmastectomy radiation therapy: The guideline task force identified several key radiation therapy questions for patients with breast cancer who undergo mastectomy.
- Oral TKI sevabertinib approved for advanced HER2-mutant NSCLC.